Endurant Capital Management LP reduced its position in shares of Insmed, Inc. (NASDAQ:INSM) by 76.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,910 shares of the biopharmaceutical company’s stock after selling 72,490 shares during the period. Endurant Capital Management LP’s holdings in Insmed were worth $714,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in INSM. Janus Henderson Group PLC grew its position in Insmed by 140.2% in the third quarter. Janus Henderson Group PLC now owns 3,960,748 shares of the biopharmaceutical company’s stock worth $123,615,000 after acquiring an additional 2,312,045 shares in the last quarter. BlackRock Inc. grew its position in Insmed by 11.7% in the fourth quarter. BlackRock Inc. now owns 7,830,604 shares of the biopharmaceutical company’s stock worth $244,159,000 after acquiring an additional 817,915 shares in the last quarter. Nexthera Capital LP grew its position in Insmed by 246.5% in the fourth quarter. Nexthera Capital LP now owns 498,921 shares of the biopharmaceutical company’s stock worth $15,556,000 after acquiring an additional 354,921 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in Insmed in the third quarter worth $9,210,000. Finally, Redmile Group LLC grew its position in Insmed by 12.9% in the fourth quarter. Redmile Group LLC now owns 2,249,262 shares of the biopharmaceutical company’s stock worth $70,132,000 after acquiring an additional 257,616 shares in the last quarter. Hedge funds and other institutional investors own 99.08% of the company’s stock.
Shares of Insmed, Inc. (NASDAQ INSM) opened at $24.31 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.72 and a quick ratio of 8.72. Insmed, Inc. has a one year low of $11.49 and a one year high of $33.94.
Several research analysts recently issued reports on INSM shares. Zacks Investment Research lowered shares of Insmed from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th. Credit Suisse Group started coverage on shares of Insmed in a research report on Wednesday, January 17th. They issued a “neutral” rating and a $31.00 target price for the company. BidaskClub upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, ValuEngine upgraded shares of Insmed from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. Insmed has a consensus rating of “Hold” and a consensus price target of $36.67.
ILLEGAL ACTIVITY NOTICE: “Insmed, Inc. (INSM) Stake Lowered by Endurant Capital Management LP” was reported by Week Herald and is owned by of Week Herald. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://weekherald.com/2018/03/20/insmed-inc-insm-stake-lowered-by-endurant-capital-management-lp.html.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.